Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Dascena

Explore full profile

Develops companion diagnostic algorithms to enable early disease intervention and improved care and patient outcomes

Oakland, United StatesFounded 2018Biotech & Life Sciences
Valuation $100–500M Latest valuation · 2020
Revenue $10–50M Latest reported FY
Headcount <100 Current team size
Total funding $50–100M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Dascena and the history behind them.

About Dascena

Dascena is a healthcare technology company specializing in the development and implementation of clinically proven machine learning algorithms to enhance patient outcomes. Operating in the healthcare sector, Dascena serves hospitals, clinics, and biopharma companies by providing advanced diagnostic tools and clinical decision support systems. The company leverages vast amounts of healthcare data to create predictive algorithms that identify diseases such as sepsis and COVID-19 earlier and with higher accuracy, enabling timely intervention by clinicians. Dascena's business model revolves around licensing its algorithms and diagnostic tools to healthcare providers and biopharma companies, generating revenue through subscription fees and service contracts. The company's innovations are backed by scientific rigor and clinical evidence, with numerous publications in peer-reviewed journals and validation through clinical trials. Dascena's mission is to drive personalized medicine by identifying the right patient for the right therapy at the right time, ultimately improving the delivery of patient care and saving lives.

Source: Dealroom company data

At a glance

Founded
2018
Headquarters
Oakland, United States
Sector
Biotech & Life Sciences
Power Law
Colt$25–100M revenue

Latest news

Press, funding announcements and product moves mentioning Dascena.

See all news

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • National Institutes of Health

Series A3 investors entered at this stage

  • Frazier Healthcare Partners
  • Euclidean Capital
  • Longitude Capital

Series B and later3 investors entered at this stage

  • Frazier Healthcare Partners
  • Euclidean Capital
  • Longitude Capital
Employees mapped 27 incl. 2 AI specialists
Founders Hidden — book a demo/100 quality score
Key operators 7 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Dascena on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Dascena on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.